Pain

What to Do After a Hit-And-Run in Georgia

Retrieved on: 
Thursday, February 29, 2024

ATLANTA, Feb. 29, 2024 /PRNewswire/ -- Hit-and-run motor vehicle accidents are not uncommon in Georgia. Every year pedestrians, bicyclists, and occupants of other cars are injured or killed in the state in these dangerous crashes. Drivers who cause them can be held responsible when they can be located.

Key Points: 
  • Every year pedestrians, bicyclists, and occupants of other cars are injured or killed in the state in these dangerous crashes.
  • "Hit-and-run drivers who cause injuries may be subject to criminal prosecution and be sued by injured parties."
  • There are steps that accident victims can take to help ensure that the driver who injured them is held accountable.
  • If the driver cannot be found, the attorney can provide advice about other potential options for receiving compensation for injuries and property damage."

Sun Life reports shows clinical intervention programs in group benefits improve health outcomes and help people return to work

Retrieved on: 
Wednesday, February 28, 2024

WELLESLEY, Mass., Feb. 28, 2024 /PRNewswire/ -- Sun Life U.S. has released reports from two clinical intervention programs offered to eligible members receiving disability or critical illness benefits.

Key Points: 
  • WELLESLEY, Mass., Feb. 28, 2024 /PRNewswire/ -- Sun Life U.S. has released reports from two clinical intervention programs offered to eligible members receiving disability or critical illness benefits.
  • The reports showed that members who used these programs experienced improved health outcomes.
  • These programs align with Sun Life's strategy to help people access the care and coverage they need by providing health services and programs that complement core health insurance.
  • AbleTo provides virtual behavioral health services to covered members receiving disability or critical illness benefits due to a cancer diagnosis.

Chill. Stick. Go.: Compass Health Brands Delivers PAINCAKES® The Cold Pack That Sticks!® Bringing Disruption to The Cold Therapy Market

Retrieved on: 
Wednesday, February 28, 2024

QUINCY, Mass., Feb. 28, 2024 /PRNewswire-PRWeb/ -- Versatile and portable, PAINCAKES® is a cold pack that sticks and provides relief to sore muscles, aches, and pains.

Key Points: 
  • Versatile and portable, PAINCAKES® is a cold pack that sticks and provides relief to sore muscles, aches, and pains.
  • Each gel cold pack features a proprietary stick-and-stay technology that's been tested and proven to stick up to 100 times.
  • "We are very excited to introduce PAINCAKES® to consumers," says Tony West, Compass Health Brands' SVP of Retail.
  • This is the latest offering from Compass Health Brands, the same company that owns over 20 brands with thousands of products.

Lionize Announces Initial Closing of $2 Million Funding Round Led by Cultivation Capital to Fuel Continued Growth in the Influencer Marketing Sector

Retrieved on: 
Wednesday, February 28, 2024

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Lionize , an innovative AI-driven influencer search tool and influencer marketing platform, today announced the initial closing of a funding round of up to $2M led by Cultivation Capital.

Key Points: 
  • NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Lionize , an innovative AI-driven influencer search tool and influencer marketing platform, today announced the initial closing of a funding round of up to $2M led by Cultivation Capital.
  • This investment marks a significant milestone in Lionize's mission to revolutionize influencer marketing through the use of AI.
  • Lionize scales influencer marketing with ease by using AI to make recruiting and managing creators your new superpower.
  • Heather Wood, Partner at Cultivation Capital, commented, "Lionize is not just innovating; they are solving a significant pain point in the influencer marketing industry.

To better align with its mission to provide software and services for a more secure world, Haystax will now be known as Secure Passage

Retrieved on: 
Wednesday, February 28, 2024

This change further aligns our team with an unwavering focus to deliver the industry's preeminent converged security products and services.

Key Points: 
  • This change further aligns our team with an unwavering focus to deliver the industry's preeminent converged security products and services.
  • Meeting a compounding need for sophisticated and converged security, Secure Passage combines the software, tools, experience, and know-how to combine and act on converged security data," said Chairman & CEO, Gary Fish.
  • Further, in Q2, Secure Passage will launch several new products, beginning with Secure Passage Dragon, a data aggregation pipeline designed to take the pain out of connecting, analyzing, and monitoring security devices.
  • Secure Passage remains committed to its mission of delivering innovative, reliable, and adaptive security solutions that safeguard against the ever-evolving threat landscape.

Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Retrieved on: 
Wednesday, February 28, 2024

ET Today

Key Points: 
  • ET Today
    CRANBURY, N.J., Feb. 28, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced results for its PL9643 MELODY-1 pivotal Phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED).
  • "We are pleased that PL9643 treatment demonstrated excellent safety and tolerability data, including superior efficacy results compared to vehicle across multiple sign endpoints."
  • The study design was based on positive Phase 2 results of PL9643 for the treatment of DED, and an end-of-Phase 2 meeting with the FDA on key elements of the pivotal Phase 3 clinical program.
  • Palatin will host a conference call and audio webcast on February 28, 2024, at 8:30 a.m. Eastern Time to discuss the PL9643 Phase 3 clinical study results in greater detail.

TRUX MARKS FIVE YEARS OF LOGISTICS MANAGEMENT

Retrieved on: 
Wednesday, February 28, 2024

Trux™, the leader in dump truck logistics technology,  marks the 5th anniversary of the launch of its flagship product.

Key Points: 
  • Trux™, the leader in dump truck logistics technology,  marks the 5th anniversary of the launch of its flagship product.
  • "We've worked hand in hand with our customers over the years to continue improving the Trux platform," said Donald Lee, President of Trux."
  • Trux Deliver is part of the Trux delivery logistics platform for dispatching haulers, monitoring material delivery, optimizing plant efficiency, E-ticketing, and customer engagement.
  • For more information about Trux or the company's other dump truck logistics solutions, visit www.truxnow.com .

New technology aiming to improve patients' outcomes in breast cancer

Retrieved on: 
Wednesday, February 28, 2024

Breast Cancer is the most common cancer in women in Europe, accounting for 1 in 4 annual cancer cases.

Key Points: 
  • Breast Cancer is the most common cancer in women in Europe, accounting for 1 in 4 annual cancer cases.
  • Breast cancer is the most common female cancer in the WHO Europe region, accounting for 1 in 4 new cancer diagnoses with an estimated incidence of more than half a million in 2020, making it the leading cause of cancer death in women.
  • [i]
    Through state-of-the-art and future-proofed technology, we can improve these outcomes for patients across Europe and more lives can be saved through faster diagnosis.
  • [ii]
    AMULET SOPHINITY™ is a digital mammography system that offers low dose, high image quality, and improved workflow with AI technology.

"Gifts of Comfort and Hope" Await at United Breast Cancer Foundation's Mattress and Pink Bag Event in Warwick, Rhode Island This April

Retrieved on: 
Tuesday, February 27, 2024

WARWICK, R.I., Feb. 27, 2024 /PRNewswire-PRWeb/ -- United Breast Cancer Foundation (UBCF) is pleased to announce the "Gifts of Comfort and Hope" Mattress & Pink Bag Event in Warwick, Rhode Island. Imagine sinking into a cloud of comfort, knowing deep down that somewhere, amongst a community of warriors, hope and support are blooming this spring. This dream becomes reality for breast cancer patients and survivors on Saturday, April 27th, 2024. In collaboration with Good360 and fellow breast cancer organization, the Gloria Gemma Breast Cancer Resource Foundation, UBCF is excited to welcome breast cancer patients and survivors throughout the day to gift 160 restorative Tempur-Pedic® mattresses and other pampering items at no cost.

Key Points: 
  • Sweet Dreams & Shared Strength: Warwick Welcomes Warriors for a Day of Renewal for Breast Cancer Patients and Survivors
    WARWICK, R.I., Feb. 27, 2024 /PRNewswire-PRWeb/ -- United Breast Cancer Foundation (UBCF) is pleased to announce the "Gifts of Comfort and Hope" Mattress & Pink Bag Event in Warwick, Rhode Island.
  • In collaboration with Good360 and fellow breast cancer organization, the Gloria Gemma Breast Cancer Resource Foundation, UBCF is excited to welcome breast cancer patients and survivors throughout the day to gift 160 restorative Tempur-Pedic® mattresses and other pampering items at no cost.
  • For those navigating the often challenging path of breast cancer, a good night's sleep can feel like a distant luxury.
  • The UBCF Mattress and Pink Bag Event is open to breast cancer patients and survivors, regardless of gender.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS

Retrieved on: 
Tuesday, February 27, 2024

NASHVILLE, Tenn., Feb. 27, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2023 financial results and provide a company update after the market closes on Tuesday, March 5, 2024.

Key Points: 
  • NASHVILLE, Tenn., Feb. 27, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2023 financial results and provide a company update after the market closes on Tuesday, March 5, 2024.
  • A conference call will be held on March 5 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.